Patents by Inventor Dorla Mirejovsky
Dorla Mirejovsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230338277Abstract: Provided is an aqueous formulation comprising cetrorelix and/or a salt thereof, an isotonicity adjuster, a pH adjuster and water, suitable for subcutaneous injection. Also provided is a method of treating a patient with cetrorelix comprising injecting the above aqueous formulation to the patient in a manner sufficient to treat the patient.Type: ApplicationFiled: April 20, 2023Publication date: October 26, 2023Applicant: BELOTECA, INC.Inventors: Frederik Defesche, Dorla Mirejovsky, Jenny Tran
-
Publication number: 20220304893Abstract: Provided is a packaging system for an oxygen-sensitive compound (a drug, such as DHE, or an excipient such as exametazime), the system including a container, a self-activated oxygen scavenger (including an iron-based or non-iron based) and an oxygen-impermeable enclosure (e.g., an aluminum pouch). Also provided is a method of producing an oxygen-sensitive compound.Type: ApplicationFiled: June 16, 2020Publication date: September 29, 2022Applicant: BELOTECA, INC.Inventors: Fred Defesche, Dorla Mirejovsky, Shanghui Sun
-
Patent number: 9295666Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.Type: GrantFiled: August 30, 2013Date of Patent: March 29, 2016Assignee: Spectrum Pharmaceuticals, Inc.Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
-
Publication number: 20140073680Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.Type: ApplicationFiled: August 30, 2013Publication date: March 13, 2014Applicant: Spectrum Pharmaceuticals, Inc.Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
-
Patent number: 8563592Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.Type: GrantFiled: April 8, 2011Date of Patent: October 22, 2013Assignee: Spectrum Pharmaceuticals, Inc.Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
-
Publication number: 20110288143Abstract: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition.Type: ApplicationFiled: April 8, 2011Publication date: November 24, 2011Inventors: Bastiaan Nuijen, Ernie Pfadenhauer, Jos H. Beijnen, Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
-
Publication number: 20090163570Abstract: Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.Type: ApplicationFiled: March 2, 2009Publication date: June 25, 2009Inventors: Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
-
Publication number: 20070185188Abstract: Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.Type: ApplicationFiled: February 9, 2007Publication date: August 9, 2007Inventors: Dorla Mirejovsky, Guru Reddy, Luigi Lenaz
-
Patent number: 7153840Abstract: This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.Type: GrantFiled: May 23, 2003Date of Patent: December 26, 2006Assignee: Sicor, Inc.Inventors: Dorla Mirejovsky, Peter Lindsay Macdonald
-
Patent number: 6906047Abstract: This invention is directed towards a ready-to-use aqueous composition of ifosfamide. In one embodiment, the invention is directed to an aqueous ifosfamide composition which comprises ifosfamide, a pharmaceutically acceptable buffer, and water. The concentration of ifosfamide in the composition may be between about 40 mM and about 400 mM. The concentration of buffer in the composition may be between about 10 mM and about 260 mM. The molar ratio of ifosfamide to buffer may be between about 0.5:1 to about 20:1. The pH of the composition may be between about 4 and about 8.Type: GrantFiled: December 13, 2002Date of Patent: June 14, 2005Assignee: Gensia Sicor Pharmaceuticals, Inc.Inventors: Dorla Mirejovsky, Michael Burkhart
-
Patent number: 6709674Abstract: The invention includes a packaged liquid composition of a pamidronate alkaline salt in a sealed storage vessel having an inner surface which is non-reactive with the pamidronate alkaline salt composition.Type: GrantFiled: May 1, 2002Date of Patent: March 23, 2004Assignee: Gensia Sicor Pharmaceuticals, Inc.Inventor: Dorla Mirejovsky
-
Publication number: 20040006041Abstract: This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.Type: ApplicationFiled: May 23, 2003Publication date: January 8, 2004Inventors: Dorla Mirejovsky, Peter Lindsay MacDonald
-
Publication number: 20030229052Abstract: This invention is directed towards a ready-to-use aqueous composition of ifosfamide. In one embodiment, the invention is directed to an aqueous ifosfamide composition which comprises ifosfamide, a pharmaceutically acceptable buffer, and water. The concentration of ifosfamide in the composition may be between about 40 mM and about 400 mM. The concentration of buffer in the composition may be between about 10 mM and about 260 mM. The molar ratio of ifosfamide to buffer may be between about 0.5:1 to about 20:1. The pH of the composition may be between about 4 and about 8.Type: ApplicationFiled: December 13, 2002Publication date: December 11, 2003Applicant: Gensia Sicor Pharmaceuticals, Inc.Inventors: Dorla Mirejovsky, Michael Burkhart
-
Publication number: 20030069211Abstract: The invention includes a packaged liquid composition of a pamidronate alkaline salt in a sealed storage vessel having an inner surface which is non-reactive with the pamidronate alkaline salt composition.Type: ApplicationFiled: May 1, 2002Publication date: April 10, 2003Inventor: Dorla Mirejovsky
-
Patent number: 6469069Abstract: Sterile pharmaceutical compositions for parenteral administration containing 2,6-diisopropylphenol (propofol) are described for use as anesthetics. The compositions comprise an oil-in-water emulsion of propofol additionally comprising an amount of sulfite sufficient to prevent significant growth of microorganisms for at least 24 h after adventitious contamination.Type: GrantFiled: September 8, 2000Date of Patent: October 22, 2002Assignee: Gensia Sicor Pharmaceuticals, Inc.Inventors: Dorla Mirejovsky, Liananingsih Tanudarma, Dilip R. Ashtekar
-
Patent number: 6147122Abstract: Sterile pharmaceutical compositions for parenteral administration containing 2,6-diisopropylphenol (propofol) are described for use as anesthetics. The compositions comprise an oil-in-water emulsion of propofol additionally comprising an amount of sulfite sufficient to prevent significant growth of microorganisms for at least 24 h after adventitious contamination.Type: GrantFiled: February 10, 1999Date of Patent: November 14, 2000Assignee: Gensia Sincor Inc.Inventors: Dorla Mirejovsky, Liananingsih Tanudarma, Dilip R. Ashtekar
-
Patent number: 6136850Abstract: Methods and compositions for inhibiting the formation of proteinaceous and/or lipid deposits on a contact lens are disclosed. In one embodiment, the present method comprises contacting a contact lens being worn in a mammalian eye with at least one ophthalmically acceptable antioxidant component in an amount effective to inhibit the formation of at least one of proteinaceous deposits and lipid deposits on the contact lens in the eye.Type: GrantFiled: February 12, 1993Date of Patent: October 24, 2000Assignee: AllerganInventors: John Y. Park, James N. Cook, Dorla Mirejovsky, Steven S. Matsumoto
-
Patent number: 4743588Abstract: Compositions and methods useful for enhancing the transdermal and transmembrane drug delivery of topical and systemic agents. The compositions and methods comprise the active agent together with an effective amount of certain amides of heterocyclic amines as defined herein as penetration enhancers and topically administering to human or animal skin or other membranes the resulting compositions.Type: GrantFiled: June 13, 1984Date of Patent: May 10, 1988Assignee: Allergan Pharmaceuticals, Inc.Inventors: Dorla Mirejovsky, Harun Takruri